GC-508

N/A

Report date: 2023/08/16 11:30:15

Base Information

Drug NameGC-508
Drug Alias NameGC-508GC508
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD7Anti-BCMAT lymphocyte replacements
TargetsT-cell antigen CD7B-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGracell Biotechnologies (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGracell Biotechnologies (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A